奈达铂或顺铂联合吉西他滨治疗中晚期NSCLC的临床效果及其安全性评价

奈达铂或顺铂联合吉西他滨治疗中晚期NSCLC的临床效果及
其安全性评价
薛雁鸿;王来成;胡丽丽;杨波
【期刊名称】《中国药物警戒》
【年(卷),期】2018(015)003
【摘要】目的比较两种含吉西他滨非小细胞肺癌(NSCLC)化疗方案,吉西他滨(GEM)联合顺铂(DDP)与吉西他滨(GEM)联合奈达铂(NDP),分析其疗效及不良反应(ADR)上的差异,为临床制定个体化给药方案提供参考.方法选择徐州医科大学附属医院2015年1月至2017年4月诊断为中晚期非小细胞肺癌的患者58例,GEM 联合NDP方案组(GN方案)30例,GEM联合DDP方案组(GP方案)28例,治疗周期为21天,每次化疗周期记录不良反应,第3次化疗开始前检测肿瘤CT进行疗效评估,开展两方案不良反应及疗效比较.结果GN方案有效率为43.33％,GP方案有效率为42.86％,二者在疗效上无显著性差异(P>0.05);GN方案消化道症状的发生率低于GP方案(P<0.05),两方案在NEUT、WBC、HGB及PLT计数下降及肝肾毒性上的差异均无统计学意义(P>0.05).结论GN方案与GP方案疗效接近,而GN方案的胃肠道反应更轻,且无需水化治疗,耐受性好.从有效性、安全性等考虑,GN方案可作为GP方案替代治疗方案.%Objective To compare the two gemcitabine related chemotherapy regimens (gemcitabine (GEM) in combination with cisplatin (DDP) or nedaplatin(NDP)) on non-small cell lung cancer(NSCLC), analyze the differences of curative effect and adverse drug reactions (ADR), and provide reference to clinical individualized regimen. Methods The 58 cases diagnosed with NSCLC patients in Xuzhou Medical University Affiliated
Hospital between January 2015 and April 2017 were divided into 2 groups, 30 cases of NDP combined with GEM (GN), 28 cases of DDP combined with GEM (GP), treatment cycles within 21 days. Recorded ADR of each cycle of chemotherapy regimens; evaluated curative effect using CT when the third cycle chemotherapy had been finished, then analyzed the adverse reactions and curative effect between the two regimens. Results GN regimen effective rate is 43.33％, GP is 42.86％, there is no significant difference (P>0.05). Gastrointestinal symptoms incidences of NP are lower than GP regimens (P<0.05), and there are no statistical significant differences in decreasing of NEUT, WBC, HGB and PLT, liver toxicity, kidney toxicity (P>0.05). Conclusion Curative effect of GN is similar to GP, and the gastrointestinal reaction of GN is slighter, good tolerance, without hydration treatment. From the effectiveness and safety considerations, GN scheme is comparable with GP for treatment options.
【总页数】4页(P136-139)
【作者】薛雁鸿;王来成;胡丽丽;杨波
【作者单位】徐州医科大学附属医院西院/中煤第五建设公司职工医院药剂科, 江苏徐州 221006;徐州医科大学附属医院药学部, 江苏徐州 221006;徐州医科大学附属医院药学部, 江苏徐州 221006;徐州医科大学临床学院, 江苏徐州 221006;徐州市食品药品监督管理局, 江苏徐州 221018
【正文语种】中文
【中图分类】R979.11
【相关文献】
1.奈达铂对照顺铂同步放疗治疗中晚期宫颈癌的近期疗效及安全性评价 [J], 郑积华;王辉;谢波;黄雪琴;周娟;徐志勇;黄彦泽;文英娟;张为民
2.吉西他滨联合奈达铂与吉西他滨联合顺铂治疗老年晚期非小细胞肺癌的临床研究[J], 刘淑;郑玉龙;王伟;周学义
3.吉西他滨联合奈达铂与吉西他滨联合顺铂用于尿路上皮癌术后化疗的临床疗效和安全性比较 [J], 卢猛;滕井卫;毛立军;李望;温儒民;陈家存;王军起
4.吉西他滨联合奈达铂与吉西他滨联合顺铂用于尿路上皮癌术后化疗的临床疗效和安全性比较 [J], 卢猛;滕井卫;毛立军;李望;温儒民;陈家存;王军起;
5.奈达铂联合吉西他滨对比顺铂联合吉西他滨一线治疗晚期肺鳞癌随机对照临床研究 [J], 陈胜佳;朱凯;林金兰;张晶;徐振武;庄武;徐海鹏
因版权原因，仅展示原文概要，查看原文内容请购买。